CA3098360A1 - Magnesium threonate compositions and uses thereof - Google Patents

Magnesium threonate compositions and uses thereof Download PDF

Info

Publication number
CA3098360A1
CA3098360A1 CA3098360A CA3098360A CA3098360A1 CA 3098360 A1 CA3098360 A1 CA 3098360A1 CA 3098360 A CA3098360 A CA 3098360A CA 3098360 A CA3098360 A CA 3098360A CA 3098360 A1 CA3098360 A1 CA 3098360A1
Authority
CA
Canada
Prior art keywords
dosage form
magnesium
threonate
day
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3098360A
Other languages
English (en)
French (fr)
Inventor
Guosong Liu
Fei Mao
Jason Gregory WEINGER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neurocentria Inc
Original Assignee
Neurocentria Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurocentria Inc filed Critical Neurocentria Inc
Publication of CA3098360A1 publication Critical patent/CA3098360A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3098360A 2018-04-25 2019-04-24 Magnesium threonate compositions and uses thereof Pending CA3098360A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862662756P 2018-04-25 2018-04-25
US62/662,756 2018-04-25
PCT/US2019/028903 WO2019209943A1 (en) 2018-04-25 2019-04-24 Magnesium threonate compositions and uses thereof

Publications (1)

Publication Number Publication Date
CA3098360A1 true CA3098360A1 (en) 2019-10-31

Family

ID=68291941

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3098360A Pending CA3098360A1 (en) 2018-04-25 2019-04-24 Magnesium threonate compositions and uses thereof

Country Status (9)

Country Link
US (2) US11717501B2 (https=)
EP (1) EP3784227A4 (https=)
JP (2) JP2021522344A (https=)
KR (1) KR20210005662A (https=)
CN (3) CN112384210A (https=)
AU (2) AU2019261406A1 (https=)
BR (1) BR112020021812A2 (https=)
CA (1) CA3098360A1 (https=)
WO (1) WO2019209943A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112384210A (zh) 2018-04-25 2021-02-19 纽罗森特里亚股份有限公司 苏糖酸镁组合物及其用途
MY197760A (en) 2020-06-01 2023-07-13 Celagenex Res India Pvt Ltd Novel synergistic medicinal compositions for treating dysfunctional d-serine signaling
JP7805352B2 (ja) * 2020-08-28 2026-01-23 ディーエフアイ ユーエスエー，エルエルシー Ｌ－キシロン酸からｌ－トレオン酸塩を生産する方法
CN114304610A (zh) * 2021-12-24 2022-04-12 苏州麦轮生物科技有限公司 一种含有苏糖酸镁的营养补充剂及其应用
WO2024232931A1 (en) * 2023-05-11 2024-11-14 Yon Doo Ough Apparatus and method for contact free delivery and administration of magnesium as a drug
CN119504413A (zh) * 2025-01-20 2025-02-25 浙江天启生化股份有限公司 一种l-苏糖酸镁合成方法及应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6010718A (en) * 1997-04-11 2000-01-04 Abbott Laboratories Extended release formulations of erythromycin derivatives
GB0009522D0 (en) * 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
EP1524981B1 (en) * 2002-07-29 2009-03-11 Glaxo Group Limited Sustained release formulations comprising lamotrigine
CN113143901A (zh) * 2007-03-22 2021-07-23 纽罗森特里亚股份有限公司 镁组合物及其用途
US8163301B2 (en) 2007-03-22 2012-04-24 Magceutics, Inc. Magnesium compositions and uses thereof for metabolic disorders
EP2448413A4 (en) 2009-07-01 2013-02-13 Magceutics Inc SLOW RELEASE MAGNESIUM COMPOSITION AND USES THEREOF
RU2607595C2 (ru) * 2010-02-03 2017-01-10 Фарма Ту Б Лтд. Составы разагилина с пролонгированным высвобождением и их применение
WO2017044486A1 (en) * 2015-09-11 2017-03-16 Neurocentria, Inc. Threonate compounds and methods of use thereof
CN105326855A (zh) * 2015-10-27 2016-02-17 南京大学 易吸收复合夹层式螯合镁钙片
CN105326955B (zh) * 2015-11-02 2019-04-12 北京市眼科研究所 一种治疗睑缘炎的组合物及其制备方法
US10617713B2 (en) * 2016-03-08 2020-04-14 Neurocentria, Inc. Methods of modifying neuronal function by changing intracellular magnesium levels
CN107625776A (zh) * 2016-07-19 2018-01-26 无锡脑镁素生物医药科技有限公司 用于改善睡眠的镁组合物及其用途
CN106360734A (zh) * 2016-09-28 2017-02-01 张家港威胜生物医药有限公司 一种同时具有减肥和美容作用的组合物及其制备方法与用途
WO2018200885A1 (en) * 2017-04-26 2018-11-01 Neurocentria, Inc. Magnesium compositions and methods of use
CN112384210A (zh) 2018-04-25 2021-02-19 纽罗森特里亚股份有限公司 苏糖酸镁组合物及其用途

Also Published As

Publication number Publication date
CN120168449A (zh) 2025-06-20
JP2021522344A (ja) 2021-08-30
CN112384210A (zh) 2021-02-19
EP3784227A4 (en) 2022-03-02
AU2019261406A1 (en) 2020-12-17
US20240156761A1 (en) 2024-05-16
US11717501B2 (en) 2023-08-08
KR20210005662A (ko) 2021-01-14
AU2025201393A1 (en) 2025-03-20
BR112020021812A2 (pt) 2021-02-23
WO2019209943A1 (en) 2019-10-31
JP2025011238A (ja) 2025-01-23
US20190328689A1 (en) 2019-10-31
CN120241690A (zh) 2025-07-04
EP3784227A1 (en) 2021-03-03

Similar Documents

Publication Publication Date Title
US20240156761A1 (en) Magnesium Threonate Compositions and Uses Thereof
TWI241911B (en) Sustained release ranolazine formulations
KR100530546B1 (ko) 구강내에서 신속하게 붕괴되는 정제용 서방성 미립자가함유된 조성물 및 그의 제조 방법
US6426091B1 (en) Sustained-release theophylline tablet
EP2921170A1 (en) Combination immediate release controlled release levodopa/carbidopa dosage forms
JPH0696524B2 (ja) バルプロ酸をベ−スとした新規薬剤組成物及びその製法
CN109475510B (zh) 普瑞巴林的延长释放剂型
US4867987A (en) Pharmaceutical product for the sustained release of ibuprofen
US20030224045A1 (en) Combination immediate release sustained release levodopa/carbidopa dosage forms
JP2022522005A (ja) Ｔｂｎ、又はその塩もしくは水和物を含む薬物組成物及びその製造方法
JPWO2005039542A1 (ja) 口腔内崩壊錠用の薬物含有被覆微粒子
JP2665858B2 (ja) 持効性塩酸オキシブチニン製剤
WO2006002032A1 (en) Sustained release neutralized divalproex sodium
CN101584683A (zh) 美托拉宗缓释胶囊及其制备方法
JP2016539171A (ja) アセブロフィリン及び疎水性徐放性基剤を含む徐放性薬学組成物
WO2001028516A2 (en) Sustained-release formulations for treating cns-mediated disorders
EP1815850B1 (en) Controlled release formulation of divalproic acid and its derivatives
US20070160667A1 (en) Controlled release formulation of divalproex sodium
US20070178149A1 (en) Levodopa compositions
CN110384669A (zh) 一种司美替尼及其衍生物的新剂型及制备方法
US20240350420A1 (en) Pharmaceutical compositions and methods for treating hyperhidrosis
WO2007081341A1 (en) Controlled release formulation of divalproic acid and its derivatives
JP2016538315A (ja) アセブロフィリン及び親水性徐放性基剤を含む徐放性薬学組成物
WO2021036230A1 (zh) 一种雷诺嗪缓释组合物及其制备方法
HK1105891A (en) Controlled release formulation of divalproic acid and its derivatives

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240422

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250407

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250407

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20250516

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20250915

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20251119

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20251119

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251119

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260401

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260401